Switching to aflibercept versus continuing bevacizumab for treatment-resistant neovascular age-related macular degeneration: a one-year comparative observational study.
Yngvil Solheim HusumMorten Carstens MoeRagnheiður BragadóttirØystein Kalsnes JørstadPublished in: Acta ophthalmologica (2021)
The study suggests that the possibility of switching eyes with treatment-resistant nAMD to aflibercept leads to a modest visual benefit compared with continuing first-line bevacizumab therapy.